Reduction in Asymmetric Dimethylarginine Plasma Levels by Coenzyme Q10 Supplementation in Patients With Type 2 Diabetes Mellitus Pubmed



Hosseinzadehattar MJ^{1, 2} ; Mohammadi RK^{1, 2} ; Eshraghian MR³ ; Nakhjavani M⁴ ; Khorrami E^{1, 2} ; Ebadi M⁴ ; Esteghamati A⁴ Show Affiliations
Source: Minerva Endocrinologica Published:2015

Abstract

Aim. According to many studies, supplementation with Coenzyme Q10 (CoQ10) yields beneficial results in terms of endothelial function in type 2 diabetes mellitus. Despite these promising results, data elucidating the effect of CoQ10 on plasma levels of asymmetric dimethylarginine (ADMA), as a recently discussed cardiovascular risk factor, is lacking. This study was designed to investigate the effect of CoQ10 supplementation on endothelial function, specifically by evaluating plasma ADMA levels. Methods. Sixty-four type 2 diabetic patients were randomly assigned to two groups; either receiving 200mg/d oral dose of CoQ10 (N.=31) or receiving placebo (N.=33) for 12 weeks. Clinical and biochemical assessments were performed before and after the trial for evaluating ADMA, serum nitrite and nitrate (NOx), hemoglobin A1c and lipid profile. Results. The intervention resulted in a significant improvement in ADMA, NOx , low-density lipoprotein and hemoglobin A1c levels in CoQ10 compared to placebo group. Interestingly, difference in changes of these parameters were also significant (P=0.01, 0.03, 0.04 and 0.03, respectively). Conclusion. Supplementation with CoQ10 yields beneficial effects on ADMA levels, leading to decreased diabetic cardiovascular events. © This document is protected by international copyright laws.